Innovent Approved to Launch Humira Biosimilar in China

Suzhou Innovent Bio was approved by China's NMPA to market Sulinno® (adalimumab), a Humira® biosimilar. Sulinno, a recombinant human anti-TNF-α monoclonal antibody, is indicated to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. Sulinno is Innovent's third monoclonal antibody drug to hit the market, joining Tyvyt® , the company's PD-1 mAb indicated for Hodgkin's lymphoma, and Byvasda® , an Avastin biosimilar for NSCLC and colorectal cancer. Innovent noted that Sulinno is the company's first product approved for a non-oncology indication. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //